TNF Alpha Inhibitors Market Report 2026

TNF Alpha Inhibitors Market Overview

• TNF Alpha Inhibitors market size has reached to $43.83 billion in 2025 • Expected to grow to $50.58 billion in 2030 at a compound annual growth rate (CAGR) of 3% • Growth Driver: Rising Geriatric Population Boosting Tnf Alpha Inhibitors Market • Market Trend: Major Companies Opting For Strategic Collaborations To Broaden Tnf Alpha Inhibitor Market And Product Portfolios • North America was the largest region in 2025.

What Is Covered Under TNF Alpha Inhibitors Market?

TNF alpha inhibitors refer to medications that are used to treat inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis and that help to reduce or eliminate inflammation. TNF inhibitors may increase the risk of skin cancer, particularly non-melanoma skin cancers like squamous cell carcinoma. The main types of drugs in TNF alpha inhibitors market are remicade (infliximab), enbrel (etanercept), humira (adalimumab), cimzia (certolizumab pegol), and simponi (golimumab). Remicade is a prescription medication for people with moderately to severely active Crohn's disease who haven't responded to other treatments. The different routes of administration include oral, subcutaneous, intravenous, and others and involve various types of diseases such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, ankylosing spondylitis, and others.

What Is The TNF Alpha Inhibitors Market Growth Forecast?

The tnf alpha inhibitors market size is expected to see steady growth in the next few years. It will grow to $50.58 billion in 2030 at a compound annual growth rate (CAGR) of 3.0%. The growth in the forecast period can be attributed to growth in inflammatory bowel disease cases, increasing biosimilar penetration, expanding patient access programs, development of safer formulations, rising healthcare spending. Major trends in the forecast period include growing adoption of biologic anti inflammatories, rising use in autoimmune disease management, shift toward biosimilar TNF inhibitors, expansion of subcutaneous administration, increased long term therapy utilization.

Global TNF Alpha Inhibitors Market Segmentation

1) By Drug: Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab) 2) By Route Of Administration: Subcutaneous, Intravenous, Other Route Of Administration 3) By Disease Type: Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types

What Is The Driver Of The TNF Alpha Inhibitors Market?

An increasing geriatric population is expected to propel the growth of the Tnf alpha inhibitors market going forward. The geriatric population, or elderly population, refers to people who are 65 years old or older. Ageing is more susceptible to autoimmune disorders and associated with increased inflammatory activity in the blood, and TNF-alpha inhibitors have been shown to be effective in reducing inflammation and atherosclerosis in the geriatric population. For instance, in January 2024, according to the Population Reference Bureau, a US-based non-profit organization, reported that the number of Americans aged 65 and older is expected to rise from 58 million in 2022 to 82 million by 2050, marking a 47% increase. As a result, this age group’s proportion of the total U.S. population will grow from 17% to 23% during this period. Therefore, the increasing geriatric population is driving the growth of the Tnf alpha inhibitors industry.

Key Players In The Global TNF Alpha Inhibitors Market

Major companies operating in the tnf alpha inhibitors market are Pfizer Inc., Johnson & Johnson, Janssen Biotech Inc., AbbVie Inc., Amgen Inc., Sandoz International GmbH, Cadila Healthcare Limited, Intas Pharmaceuticals Ltd., Samsung Bioepis Co. Ltd., Celltrion Healthcare Co. Ltd., AryoGen Pharmed Co. Ltd., EPIRUS Biopharmaceuticals Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Apotex Inc.

Global TNF Alpha Inhibitors Market Trends and Insights

Major companies operating in the TNF alpha inhibitor market are integrating their efforts in adopting strategic collaborations to expand their product portfolios and make TNF-blockers available to patients. Product distribution, in this scenario, refers to the process of making products, such as TNF-alpha inhibitors, available for purchase by dispersing them through the market. For instance, in June 2023, Mark Cuban Cost Plus Drug Company, a US-based pharmaceutical company, partnered with Coherus BioSciences Inc., a US-based biopharmaceutical company, to offer Mark Cuban Cost Plus Drug Company customers YUSIMRY (adalimumab-aqvh), a biosimilar of HUMIRA (adalimumab injection). YUSIMRY is a tumor necrosis factor (TNF) blocker approved to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa, as well as to lessen the signs and symptoms of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. This arrangement is a component of Coherus' biosimilar strategy, which aims to take advantage of its superior manufacturing and supply chain management capabilities to produce safe and efficient biosimilars with guaranteed, dependable supply.

What Are Latest Mergers And Acquisitions In The TNF Alpha Inhibitors Market?

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics PLC for $27.8 billion. This acquisition complies with Amgen's fundamental business goal of providing patients with critical diseases with cutting-edge medications that significantly improve their lives. Horizon Therapeutics PLC is a US-based biopharmaceutical company involved in the development and marketing of TNF inhibitors for the treatment of RA (rheumatoid arthritis).

Regional Insights

North America was the largest region in the TNF alpha inhibitors market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the TNF Alpha Inhibitors Market?

The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the TNF Alpha Inhibitors Market Report 2026?

The tnf alpha inhibitors market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tnf alpha inhibitors industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.